AMRA Medical

23/04/2026

New AMRA Research Assessing the Impact of AMC in CKD Published in Clinical Journal of the American Society of Nephrology!

AMRA Medical researchers recently set out to answer the question: does muscle composition identify high-risk individuals with chronic kidney disease? The answer showed that adverse muscle composition (AMC), characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD).

Over a mean follow-up period of 3.6 years, individuals with CKD and AMC showed a markedly increased risk of all-cause mortality, with an unadjusted hazard ratio of 6.17. Importantly, this association remained significant even after adjusting for demographic, lifestyle, and clinical factors, with a hazard ratio of 4.21.

These findings highlight AMC as a clinically meaningful phenotype, enabling broader stratification of high-risk individuals and supporting the value of MRI-based muscle biomarkers in clinical trials across chronic diseases.

Read the full release from AMRA: https://amramedical.com/does-muscle-composition-identify-high-risk-individuals-in-chronic-kidney-disease-new-amra-medical-study-says-yes-reveals-strong-link-to-mortality/

21/04/2026

Job Opportunity!!
We are looking for a temporary replacement for our Office Coordinator, who will be on parental leave during the period June 2026–August 2027. You are responsible for administrative tasks related to workplace wellbeing and maintaining order at our head office in Linköping. You are the main point of contact for office-related matters, both internally and for external partners.

👉 Read more here: https://amramedical.teamtailor.com/jobs/7554215-office-coordinator-till-amra-medical

17/04/2026

What an amazing Day Two we’ve had here at the 3rd Annual GLP-1-Based Therapeutics Summit! The sessions expanded the conversation beyond cardiometabolic disease, highlighting just how quickly the therapeutic horizon for GLP-1s is evolving.

A major theme throughout the day was about exploring the potential of GLP-1-based therapies in areas such as neurodegenerative disease, aging, addiction, and women’s health, reinforcing the growing idea that these therapies may extend their benefit beyond weight loss into new disease areas.

The day concluded with a forward-looking perspective: GLP-1 therapies are no longer confined to diabetes or obesity. Instead, they are emerging as a foundational platform for a new generation of treatments, where personalization and expanded applications will define the next wave of innovation.

“What stood out from this meeting is how the conversation has shifted towards what these therapies can do beyond weight loss and importantly, how well we can measure their effects, " says AMRA’s Chief Globalization Officer, Leanna Kellerman. “This is something that AMRA has kept in mind as we continue to pioneer development of MRI-based methods and measures for metabolic research and beyond, and we couldn’t be more excited about the future of the field after this conference.”

Want to connect with AMRA to learn more about how we’re reshaping MRI-based biomarkers for metabolic disease research? Reach out to us at info@amramedical.com.

15/04/2026

AMRA has wrapped up Day One at the 3rd Annual GLP-1-Based Therapeutics Summit here in Boston, and today has made one thing clear: we’ve officially moved beyond the first wave of GLP-1 success into a far more complex and competitive phase of innovation!

Across sessions, conversations centered on combination therapies, expanding into new indications like kidney and liver disease, and unlocking broader clinical impact through more personalized approaches.

Importantly, the discussion on Day One shifted toward how we evaluate these therapies. A key highlight was AMRA’s session, “Reshaping the Standard: MRI Muscle Composition for Treatment Evaluation and Differentiation in Metabolic Disease and Beyond,” presented by CSO Dr. Jennifer Linge. Drawing on nearly two decades of research, the session highlighted how AMRA’s standardized MRI muscle biomarkers enable consistent, interpretable assessment of muscle composition. Central to this was the use of weight- and BMI-invariant muscle volume Z-Scores, which uncover treatment effects independent of body weight. As therapies continue to drive significant weight loss, these insights are becoming critical to understanding true treatment effects, individual response, and opportunities for differentiation across GLP-1 therapies.

Stay tuned to find out what we learn from tomorrow’s highly-anticipated Day Two! If you’re in Boston this week for the Summit and would like to connect with AMRA onsite, reach out to us at info@amramedical.com.

09/04/2026

We are so excited to see the launch of the new Industry Collaborative from the FSHD Society, in collaboration with SOLVE FSHD and the FSHD Clinical Trial Research Network!

This new initiative aims to bring together stakeholders across industry & academia to improve how clinical trials in FSHD are designed, executed, and evaluated.

Here at AMRA, we’re proud to support this effort by contributing our experience in applying quantitative MRI to neuromuscular diseases, including FSHD. For the last decade, we’ve worked alongside collaborators in the field to help develop standardized, global multi-site imaging approaches enabling consistent, high-quality data generation across trials and geographies.

We’re looking forward to seeing how this collaborative effort advances the field and contributes to more efficient and informative clinical trials in FSHD!

⬇️ Read the full release from the FSHD Society below.

“Access to high-quality clinical trial and natural history data is critical for improving trial design for rare diseases. This research collaboration creates a rigorous framework for generating insights that individual FSHD programs cannot achieve in isolation.”

We're excited to announce our collaboration with Solve FSHD and the FSHD Clinical Trial Research Network to speed the delivery of effective treatments to individuals living with FSHD.

Read the full press release: https://www.fshdsociety.org/2026/04/08/industry-collab-launch/

12/03/2026

Be sure to stop by today’s poster sessions if you are at ICFSR 2026!

Hanna Heering, MScEng will be presenting Poster No. 184: “Can normative data for muscle ageing be inferred from cross-sectional cohort data? A large scale investigation using longitudinal UK Biobank imaging data” in the Sarcopenia category.

AMRA’s CSO, Dr. Jennifer Linge, will also be presenting Poster No. 178: “Muscle abnormalities in heart failure detected using MRI-based muscle composition”.

We’re excited to be part of the conversation around advancing muscle research and look forward to discussing how MRI-based muscle composition biomarkers can support studies in sarcopenia, muscle wasting, and beyond.

Read more about AMRA at ICFSR 2026 here -> https://amramedical.com/catch-the-latest-amra-research-on-muscle-composition-aging-and-heart-failure-icfsr-2026/

11/03/2026

Are you attending the ICFSR Conference in Washington this week?

Make sure to stop by the Thursday, March 12th poster session to see Dr. Jennifer Linge, CSO at AMRA, present Poster No. 178: “Muscle abnormalities in heart failure detected using MRI-based muscle composition” in the Sarcopenia category.

Our team onsite is looking forward to connecting with the community and discussing how advanced MRI-based muscle assessment biomarkers can deepen our understanding of muscle composition in sarcopenia and frailty research.

Read more about AMRA at ICFSR 2026 here -> https://amramedical.com/catch-the-latest-amra-research-on-muscle-composition-aging-and-heart-failure-icfsr-2026/

05/03/2026

Catch the Latest AMRA Research On Muscle Composition, Aging, and Heart Failure @ ICFSR 2026!

This March 10-12th, AMRA Medical is pleased to be attending the 16th Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR 2026), in Washington, DC!

This year, our team is excited to contribute to the conversation and share findings from two studies using our MRI-based muscle assessment biomarkers in sarcopenia and frailty research:

Poster #178: “Muscle abnormalities in heart failure detected using MRI-based muscle composition”

Poster #184: “Can normative data for muscle ageing be inferred from cross-sectional cohort data? A large scale investigation using longitudinal UK Biobank imaging data”

If you’ll be in DC for ICFSR, make sure to stop by and learn more about our latest findings on muscle composition, aging, and heart failure!

We also encourage you to reach out to any of our attending team members to set up a time to discuss how AMRA’s MRI-based fat and muscle biomarkers can help you transform your trials in sarcopenia, muscle wasting, and beyond.

Contact us via info@amramedical.com. We can’t wait to see you in DC!

03/03/2026

We are looking for our next team member to join our Imaging team.

As an MRI Scientist, you will be part of the Imaging team and work with the development of new acquisition and image analysis methodology, as well as development of new biomarkers. You lead the corresponding scientific work in terms of conducting, documenting and presenting the research, development and validation.

Read more about this opportunity and apply here: https://amramedical.com/about-us/career/

25/02/2026

Come chat with the AMRA Team at MDA 2026!

AMRA is gearing up to attend the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8–11 in Orlando! As one of the premier global meetings dedicated to advancing research, clinical care, and therapeutic development across neuromuscular diseases, MDA 2026 brings together leading clinicians, scientists, industry partners, and patient advocates committed to improving outcomes for individuals living with muscular dystrophy and related disorders.

Our team will be on site in Orlando and welcomes the opportunity to connect. If you are attending MDA 2026, we invite you to reach out to schedule a conversation about how AMRA can help power your neuromuscular trials with gold-standard muscle composition analysis. You can contact our team directly using their info below, or email info@amramedical.com to arrange a meeting.

We look forward to engaging with the community to explore how AMRA’s advanced imaging biomarkers can strengthen clinical trials and deepen our understanding of the future of neuromuscular disease research.

See you there!

Markus Karlsson, PhD
Conrad Maurais, MBA

23/02/2026

New Opportunity - Software Engineer!
Grow into an expert generalist in medical software.

Join our expanding team to build reliable systems that truly matter, collaborate closely with users and experienced colleagues, and develop across the full software lifecycle while deepening your technical expertise.

Read more about this position here: https://amramedical.com/about-us/career/

20/02/2026

Connect with the AMRA Team at the KDA 2026 Meeting in Orlando, Florida!

This year, AMRA is looking forward to attending the 2026 edition of the Kennedy’s Disease Association’s International Patient and Scientific Conference. The meeting, which runs from February 27th to March 3rd in Orlando, aims to advance “awareness, collaboration, and research toward a cure for Kennedy’s Disease.”

The AMRA team will be on site in Orlando, and is eager to set up time to chat about how AMRA can help you power your neuromuscular trials with our MRI-based biomarker solutions. If you’ll be at the meeting, reach out to any of our attending team members below, or reach out to info@amramedical.com.

We can’t wait to contribute to the conversation at KDA 2026!

Markus Karlsson, PhD
Mary Foltz, PhD
Conrad Maurais, MBA